Abstract
We report the 1 year follow-up of 3 children affected by non-paraneoplastic Opsoclonus-Myoclonus Syndrome (OMS) resistant to conventional therapies (steroids, ACTH and intravenous immunoglobulins) who were treated with an anti CD20 monoclonal antibody (rituximab). Treatment response was recorded on the basis of an international score at 0, 3, 6, 9 and 12 months. Despite the long disease duration and the numerous previously administered treatments, all patients underwent rapid and persistent neurological recovery following rituximab administration, thus suggesting a potential role of this drug even in pre-treated patients.
| Original language | English |
|---|---|
| Pages (from-to) | 192-195 |
| Number of pages | 4 |
| Journal | European Journal of Paediatric Neurology |
| Volume | 16 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Mar 2012 |
Fingerprint
Keywords
- Opsoclonus-myoclonus syndrome
- Paraneoplastic syndromes
- Rituximab
- Treatment
ASJC Scopus subject areas
- Clinical Neurology
- Pediatrics, Perinatology, and Child Health
Cite this
Response to rituximab in 3 children with opsoclonus-myoclonus syndrome resistant to conventional treatments. / Battaglia, Teresa; De Grandis, Elisa; Mirabelli-Badenier, Marisol; Boeri, Luca; Morcaldi, Guido; Barabino, Paola; Intra, Chiara; Naselli, Francesca; Pistoia, Vito; Veneselli, Edvige; Conte, Massimo.
In: European Journal of Paediatric Neurology, Vol. 16, No. 2, 03.2012, p. 192-195.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Response to rituximab in 3 children with opsoclonus-myoclonus syndrome resistant to conventional treatments
AU - Battaglia, Teresa
AU - De Grandis, Elisa
AU - Mirabelli-Badenier, Marisol
AU - Boeri, Luca
AU - Morcaldi, Guido
AU - Barabino, Paola
AU - Intra, Chiara
AU - Naselli, Francesca
AU - Pistoia, Vito
AU - Veneselli, Edvige
AU - Conte, Massimo
PY - 2012/3
Y1 - 2012/3
N2 - We report the 1 year follow-up of 3 children affected by non-paraneoplastic Opsoclonus-Myoclonus Syndrome (OMS) resistant to conventional therapies (steroids, ACTH and intravenous immunoglobulins) who were treated with an anti CD20 monoclonal antibody (rituximab). Treatment response was recorded on the basis of an international score at 0, 3, 6, 9 and 12 months. Despite the long disease duration and the numerous previously administered treatments, all patients underwent rapid and persistent neurological recovery following rituximab administration, thus suggesting a potential role of this drug even in pre-treated patients.
AB - We report the 1 year follow-up of 3 children affected by non-paraneoplastic Opsoclonus-Myoclonus Syndrome (OMS) resistant to conventional therapies (steroids, ACTH and intravenous immunoglobulins) who were treated with an anti CD20 monoclonal antibody (rituximab). Treatment response was recorded on the basis of an international score at 0, 3, 6, 9 and 12 months. Despite the long disease duration and the numerous previously administered treatments, all patients underwent rapid and persistent neurological recovery following rituximab administration, thus suggesting a potential role of this drug even in pre-treated patients.
KW - Opsoclonus-myoclonus syndrome
KW - Paraneoplastic syndromes
KW - Rituximab
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=84857367145&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84857367145&partnerID=8YFLogxK
U2 - 10.1016/j.ejpn.2011.05.013
DO - 10.1016/j.ejpn.2011.05.013
M3 - Article
C2 - 21737325
AN - SCOPUS:84857367145
VL - 16
SP - 192
EP - 195
JO - European Journal of Paediatric Neurology
JF - European Journal of Paediatric Neurology
SN - 1090-3798
IS - 2
ER -